Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka’s Q1 Pharma Sales Zoom 16.2% on Global Brands
Otsuka Holdings said on April 30 that its pharmaceutical revenue grew 16.2% year on year in the first quarter of 2024 as its four global brands continued to notch up brisk sales performances. According to its earnings report, the company’s…
To read the full story
Related Article
- Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers
August 3, 2026
- Otsuka Pharma Sales Rise 7.1% in 2025, Driven by Rexulti
February 16, 2026
- Otsuka Accelerates Pipeline Investment Centered on “Next 8” as Growth Drivers
August 1, 2025
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Otsuka Ups H1 Earnings Forecast on Brisk Business
July 29, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Otsuka Ups H1 Earnings Guidance on Bullish Global Products
July 26, 2023
- Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
May 15, 2023
- Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
February 15, 2023
- Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
November 1, 2022
- Otsuka’s H1 Pharma Sales Rise 12% on Global Brands, Profits Drop 26.2%
August 1, 2022
- Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub
May 16, 2022
- Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
February 14, 2022
- Otsuka’s 9-Month Pharma Sales Up 0.8% on Double-Digit Growth of 4 Global Brands
November 16, 2021
- Otsuka’s 4 Global Brands Likely to Hit 480 Billion Yen, 2 Years Earlier
August 10, 2021
- Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
May 14, 2021
- Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
February 15, 2021
- Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
November 16, 2020
- Otsuka’s 1st Half Pharma Sales Rise 7.6% as 4 Global Brands Fare Well
August 11, 2020
- Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
May 29, 2020
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
BUSINESS
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
- Lasker Win “Not the Finish Line” for Chugai Researchers; Next-Gen Drug Advances
September 11, 2026
- Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
September 11, 2026
- Silchester Emerges as Suzuken’s Top Shareholder with 10.03% Voting Stake
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…